Cambridge Investment Research Advisors Inc. decreased its position in Insys Therapeutics (NASDAQ:INSY) by 72.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,174 shares of the specialty pharmaceutical company’s stock after selling 29,220 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Insys Therapeutics were worth $107,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of INSY. Janney Montgomery Scott LLC purchased a new stake in shares of Insys Therapeutics in the 3rd quarter valued at approximately $135,000. Stone Ridge Asset Management LLC purchased a new stake in shares of Insys Therapeutics in the 4th quarter valued at approximately $137,000. Virtu Financial LLC grew its stake in shares of Insys Therapeutics by 96.8% in the 4th quarter. Virtu Financial LLC now owns 20,061 shares of the specialty pharmaceutical company’s stock valued at $193,000 after buying an additional 9,866 shares during the period. Raymond James & Associates grew its stake in shares of Insys Therapeutics by 93.5% in the 4th quarter. Raymond James & Associates now owns 31,008 shares of the specialty pharmaceutical company’s stock valued at $298,000 after buying an additional 14,982 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Insys Therapeutics by 50.1% in the 3rd quarter. Wells Fargo & Company MN now owns 41,516 shares of the specialty pharmaceutical company’s stock valued at $368,000 after buying an additional 13,849 shares during the period. 24.05% of the stock is owned by institutional investors and hedge funds.
NASDAQ:INSY opened at $6.96 on Friday. The company has a market cap of $498.95, a P/E ratio of -14.20 and a beta of 1.13. Insys Therapeutics has a fifty-two week low of $4.10 and a fifty-two week high of $15.02.
Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.47). The company had revenue of $31.49 million for the quarter, compared to analysts’ expectations of $34.00 million. Insys Therapeutics had a negative return on equity of 24.02% and a negative net margin of 162.07%. The business’s revenue for the quarter was down 42.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.03 EPS. analysts expect that Insys Therapeutics will post -0.83 earnings per share for the current fiscal year.
INSY has been the subject of several analyst reports. ValuEngine raised shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Zacks Investment Research cut shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd. Cann reaffirmed an “average” rating on shares of Insys Therapeutics in a research report on Friday, March 2nd. Piper Jaffray cut shares of Insys Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Friday, March 9th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Insys Therapeutics in a research report on Sunday, March 11th. Four investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $9.38.
COPYRIGHT VIOLATION WARNING: “Cambridge Investment Research Advisors Inc. Has $107,000 Stake in Insys Therapeutics (INSY)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/20/cambridge-investment-research-advisors-inc-has-107000-stake-in-insys-therapeutics-insy.html.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.